par Wautrecht, Jean-Claude 
Référence Revue médicale de Bruxelles, 30, 4, page (392-398)
Publication Publié, 2009-09
Référence Revue médicale de Bruxelles, 30, 4, page (392-398)
Publication Publié, 2009-09
Article révisé par les pairs
| Résumé : | For more than 50 years vitamin K antagonists (VKA) have been the gold standard for long-term oral anticoagulant treatment. New anticoagulants are now in extensive clinical development what will probably have a significant impact on daily practice in the near future. Compounds that specifically block activated factor X (FXa) or activated factor II (thrombin) have entered impressive phase III trials. Idraparinux is a long-active derivative from fondaparinux (synthetic pentasaccharide) and is administered subcutaneously. It inhibits indirectly FXa. Apixaban and rivaroxaban are small molecules that directly block FXa following oral administration. Dabigatran is another substance that is administered orally and directly inhibit thrombin. This article will review the potential interest of these new drugs in the modern antithrombotic care. In the meantime, we will briefly discuss two new tools that have been developed to optimalizing the classical VKA anticoagulation : anticoagulation clinics and point-of-care testing of INR that allows self-monitoring. |
